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Objectives: Inhaled antibiotics are a cornerstone of treatment for many CF patients
with chronic pseudomonal pulmonary infection, but the nebulised route is time-
consuming and limits adherence. However, recently powder forms delivered by
inhaler have become available, which are easier to administer and should improve
compliance. We wished to study the acceptance of one of these, Colobreathe® (CB),
which delivers colistin, by patients in our large adult CF clinic.
Methods: We looked at lung function and adherence in the 3 months before and
after the introduction of CB following a test dose in 17 patients (mean age 27 years,
8 male) previously taking other forms of colistin. In 9 of these we also measured
patient-related outcomes (PROMs).
Results: Sixteen patients were taking CB continuously and 1 patient month
on/month off with TOBI Podhaler®. There was no change in spirometry following
the introduction of CB (mean FEV1 % predicted: pre 64 versus post 61). However,
3 patients discontinued CB within 3 months (3 chest tightness, 1 fall in FEV1),
and a further 3 could only tolerate it once daily.
As regards PROMs, 8 patients reported improved adherence due to a marked
reduction in administration time. Although 7 patients had a signiﬁcant improvement
in their overall respiratory symptoms, 4 had increased cough, 1 had haemoptysis
and 1 reported chest tightness.
Conclusion: We have found that Colobreathe® is effective and quick to administer,
leading to improved adherence and increased patient satisfaction. Although it is a
viable alternative to nebulised colistin for many patients, a signiﬁcant proportion
develop side-effects which limit or prevent its use.
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The paranasal sinuses can constitute a niche for bacteria which can migrate to
the lungs. Nasal administration of antibiotics may be effective, but safety of this
treatment has to be established ﬁrst.
Objectives: Investigation of the pharmacokinetics (PK) of nasally administered
tobramycin (T), colistin sulphomethate sodium (CSS) and a combination of both
drugs using systemic absorption, expressed as % absorbed, as surrogate for safety.
In addition, tolerability of the nasal irrigations was examined.
Methods: Ten adult CF patients performed three different nasal irrigations: 300mg
of T, 2 million IU of CSS and 300mg of T combined with 2 million IU of
CSS. Serum concentrations T and CSS were analysed using a validated assay.
Individual PK parameters were calculated and assimilated with T and colistin serum
values using a computerized CF-based population model. Maximum serum level
(Cmax), trough serum level (Ctrough) and bioavailability (F) were calculated. T
Cmax >30mg/L and Ctrough >0.5mg/L were considered to be toxic. For colistin
toxic levels are not known. Tolerability was measured using a Visual Analog Scale
(VAS).
Results: Following the T and the combined irrigation only 2 patients had detectable
tobramycin serum levels with a Cmax < 0.06mg/L and Ctrough values< 0.015mg/L.
T bioavailability was approximately 0.76% for one patient and 0.27% for the other
patient. The results on colistin pharmacokinetics are expected in February 2014.
Tolerability for all irrigations was high, with the tolerability of CSS being the
highest.
Conclusion: Nasal irrigations with T and a combination of T and CSS resulted in
safe T serum levels and were well tolerated.
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Objectives: A post-hoc analysis of the EAGER trial assessing the impact of
tobramycin powder for inhalation (TIP™) and tobramycin inhalation solution (TIS)
across different stages of cystic ﬁbrosis (CF) lung disease categorized by baseline
FEV1% predicted.
Methods: This analysis included randomized patients from the EAGER trial
categorized into less advanced lung disease (LA): FEV1 50% predicted; and
more advanced lung disease (MA): <50% predicted.
Results: Baseline demography was similar in the TIP and TIS arms, and between
disease stages (LA, n = 300; MA, n = 217), with adults having more advanced
disease. For MA, FEV1% improved from baseline to Week 20 for TIP compared
with TIS: TIP-TIS (95%CI) of 4.0% (−1.9, 9.8). Hospitalization rates were similar
between TIP and TIS for both disease stages: OR (95%CI) 1.28 (0.70, 2.32) for
MA and 1.04 (0.57, 1.88) for LA. Use of i.v. anti-Pa antibiotics was similar in TIP
and TIS patients with MA: OR (95%CI) 1.11 (0.64, 1.92), and 1.08 (0.65, 1.80)
for LA. TIP patients in both disease stages reported higher scores for convenience,
effectiveness and global satisfaction, with no difference in medication side effects
scores between TIP and TIS. Safety proﬁle was similar between the subgroups
of the same treatment arm irrespective of disease stage, except for lung disorder
(pulmonary exacerbations) being higher for the MA patients.
Conclusion: There was a trend towards greater improvement in FEV1 with TIP
than TIS in MA patients. Safety proﬁles were similar between the disease stages
except for lung disorder. The majority of treatment satisfaction questionnaire scores
were higher for TIP, regardless of disease stage.
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Objectives: To ascertain the clinical effectiveness and safety of intravenous fos-
fomycin in an adult UK CF centre.
Methods: Following the introduction of intravenous (iv) fosfomycin in November
2011 the medical notes were reviewed for 22 separate patients who received 63
courses of iv fosfomycin during this period. All of the patients treated were
colonised with Pseudomonas aeruginosa and received fosfomycin in combination
with one or more other antibiotics. For each course of fosfomycin: treatment
dates and concurrent antibiotics were recorded as were all available peri-treatment
spirometry, weight, sputum microbiology, CRP (C-reactive protein) and white cell
counts to indicate efﬁcacy. All available renal function, hepatic function and patient
reported adverse effects were recorded to indicate safety.
Results: Treatment with fosfomycin containing regimens consistently reduced
inﬂammatory markers (CRP and white cell count) in the group. Improvements
in both spirometry and weight were not demonstrated during the treatment courses.
Despite this 58 of 63 courses were considered clinically successful. Use of
fosfomycin containing regimens was not associated with any deterioration in renal
or hepatic function. Two patients reported gastrointestinal upset which caused
treatment cessation. One patient accidentally self-adminstered a dose of fosfomycin
by bolus injection rather than infusion with no adverse effects.
Conclusion: Fosfomycin appears to be an effective and safe addition to the range
of antibiotics used to treat Pseudomonas aeruginosa in cystic ﬁbrosis. It provides
a useful alternative to aminoglycosides and colistimethate.
